Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26989692 | 1.00 | AR (0.40) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29740491 | 1.00 | AR (0.40) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17504397 | 1.00 | AR (0.40) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30716841 | 1.00 | AR (0.40) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1735574 | 0.92 | AR (0.38) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Ethoxycarbonyl Group SCHEMBL27550175 | 0.89 | AR (0.36) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Ethoxycarbonyl Group SCHEMBL27493742 | 0.89 | AR (0.36) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Propylformate SCHEMBL27569704 | 0.87 | AR (0.35) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27550216 | 0.87 | AR (0.35) | ARCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12057414 | 0.84 | AR (0.52) | ARCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730152-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | claimed |
| US-8084611-B2 | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-27 | — | — | US | claimed |
| EP-2007728-B1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131370-A1 | MELT-GRANULATED FINGOLIMOD | RATIOPHARM GMBH (DE) | 2011-10-27 | — | — | WO | claimed |
| US-20110039828-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-17 | — | — | US | claimed |
| EP-2154132-A1 | A process for preparing tetrahydroquinoline derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-02-17 | — | — | EP | claimed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | claimed |
| EP-2007728-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-31 | — | — | EP | claimed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | claimed |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-04-12 | — | — | US | claimed |
| US-12570628-B2 | Salts of obicetrapib and processes for their manufacture and intermediates thereof | NEWAMSTERDAM PHARMA B.V. (NL) | 2026-03-10 | — | — | US | disclosed |
| EP-4701626-A1 | AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION | NewAmsterdam Pharma B.V. (NL) | 2026-03-04 | — | — | EP | disclosed |
| US-20250296921-A1 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof | NEWAMSTERDAM PHARMA B.V. (NL) | 2025-09-25 | — | — | US | disclosed |
| US-12378221-B2 | Salts of obicetrapib and processes for their manufacture and intermediates thereof | NEWAMSTERDAM PHARMA B.V. (NL) | 2025-08-05 | — | — | US | disclosed |
| EP-4577207-A1 | OBICETRAPIB AND EZETIMIBE COMBINATION TREATMENT AND FIXED DOSE PHARMACEUTICAL COMPOSITIONS | NewAmsterdam Pharma B.V. (NL) | 2025-07-02 | — | — | EP | disclosed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-04-12 | — | — | US | disclosed |
| EP-1730152-A2 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095409-A2 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378221-B2 | Salts of obicetrapib and processes for their manufacture and intermediates thereof | OSTC, SOST, OCIAD1 | AR 966/4885CHRNB2 2479/4885CHRNA4 2584/4885 |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | PCSK9, LSS, DHCR7 | AR 3705/4885CHRNB2 4227/4885CHRNA4 2997/4885 |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | AR 3076/4885CHRNB2 3760/4885CHRNA4 3786/4885 |
| US-12570628-B2 | Salts of obicetrapib and processes for their manufacture and intermediates thereof | APOB, CETP, LDLR | AR 2331/4885CHRNB2 2758/4885CHRNA4 3099/4885 |
| US-20250296921-A1 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof | SOST, OSTC, BMP4 | AR 1078/4885CHRNB2 2555/4885CHRNA4 2640/4885 |
| US-20110039828-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | CETP, MTTP, NPC1L1 | AR 3076/4885CHRNB2 3760/4885CHRNA4 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.